Skip to content

A randomized controlled study on the combination of Yushen Yangluan Prescription and acupuncture treatment for patients with kidney deficiency type ovarian reserve dysfunction

A randomized controlled study on the combination of Yushen Yangluan Prescription and acupuncture treatment for patients with kidney deficiency type ovarian reserve dysfunction

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400089246
Enrollment
Unknown
Registered
2024-09-04
Start date
2024-03-01
Completion date
Unknown
Last updated
2024-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diminished ovarian reserve,DOR

Interventions

Yushen Yangluan Prescription combined with acupuncture group:Yushen Yangluan Prescription & Acupuncture
Yushen Yangluan Prescription combined with Fake Acupuncture group:Yushen Yangluan Prescription & Fake Acupuncture

Sponsors

Shanghai Traditional Chinese Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 45 years old. 2. Those who meet the criteria for Western medicine diagnosis of ovarian reserve dysfunction and traditional Chinese medicine diagnosis of kidney deficiency syndrome. 3. The patient is willing to participate in this study and actively cooperate with follow-up visits to complete clinical observation. 4. The patient signs an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Breastfeeding women. 2. Those with uncontrollable medical diseases that may interfere with or affect the research results, such as serious liver, kidney, heart, brain diseases, uncontrolled hypertension, diabetes, etc. 3. Combined with other endocrine disorders, such as polycystic ovary syndrome, thyroid dysfunction, hyperprolactinemia, etc. 4. Premature ovarian failure caused by bilateral or unilateral oophorectomy. 5. Psychiatric patients. 6. Individuals with allergies or those who are allergic to the test drug. 7. Those who can not tolerate acupuncture and moxibustion, or even fainting. 8. Combination use of ovarian function medications within three months (such as taking coenzyme Q10, dehydroepiandrosterone (DHEA), progesterone hormone, estradiol valerate tablets, etc.) 9. Participants who are currently participating or have participated in other clinical trials within the past 3 months 10. Abnormal uterine bleeding. 11. Combined with other medications for treatment. 12. Received acupuncture and moxibustion treatment within one year.

Design outcomes

Primary

MeasureTime frame
AMH, Anti-mullerian hormone;

Secondary

MeasureTime frame
AFC, Antral Follicle Counting;FSH, Basal follicle stimulating hormone;LH, luteinixing hormone;Traditional Chinese Medicine Syndrome Points;Hamilton Anxiety Scale;CDFI;Athens Insomnia Scale, AIS;Pittsburgh Sleep Quality Index, PSQI;Pictorial Blood Loss Assessment Chart, PBAC;

Countries

China

Contacts

Public ContactChen Jing

Shanghai Traditional Chinese Medicine Hospital

cj1275@126.com+86 159 2144 0609

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026